Hints and tips:
Related Special Reports
...Sandoz: Shares in the Swiss pharmaceutical company rose 4.8 per cent after it announced the European Commission had granted it the right to market Pyzchiva, a gastroenterology, dermatology, and rheumatology...
...The discussion shows the significant restructuring multinational corporations could be forced to undertake as they adapt to growing friction between China and the US and its allies....
...Large pharma companies have warned that a sharp rise in a tax on drug costs, the increase in corporation tax and the difficulty of introducing innovative products into the NHS are all reducing the draw of...
...The Swiss pharmaceuticals group is following many rivals to focus its operations on higher-value innovative treatments rather than the cheaper off-patent drugs made by Sandoz, including generic versions...
...Novartis notched a 10 per cent increase in sales in 2023 as strong performance for its heart and arthritis medicines helped Europe’s second-largest pharmaceuticals company beat its guidance for the year....
...Sandoz, for instance, is focused instead on developing generic versions of more profitable, innovative drugs that are approaching the end of their patent, Saynor says....
...The results focus on the remaining business, focused on innovative drugs, after Novartis spun out its generics division Sandoz this month....
...The Swiss group is a cleaner proposition after spinning off its generics business Sandoz in October. But there is no time to stand still. Narasimhan must show that Novartis can increase revenues....
...Ireland’s corporation tax receipts bounced back strongly in November after three months of falls, alleviating fears that a bonanza from international technology and pharmaceutical companies in the country...
...Also in the frame are the technology and pharmaceutical sectors. Their wealth of intellectual property makes them particularly adept at shifting profits....
...As part of that plan, the company is spinning off its generics drugs division Sandoz....
...Swiss pharmaceutical giant Novartis has launched a $15bn share buyback programme after raising its outlook for the year on the back of strong sales....
...AstraZeneca has signed a deal worth up to $247mn with Absci Corporation of the US to design an antibody to fight cancer, the latest tie-up in fast-expanding efforts to use artificial intelligence for drug...
...In addition, it has gone into communities to reach more people, entering a partnership with US pharmaceutical group Pfizer that has so far screened 2.5mn impoverished people for cancer....
..., an economist at Pantheon Macroeconomics, said the eurozone figures were “distorted” by the “whopping” fall in Ireland, “where the industrial production figures are heavily influenced by multinational corporations...
...Ireland is set to invest more than half of its coming corporation tax windfall in two new sovereign wealth funds, providing revenue for infrastructure projects and future economic challenges....
...Its 12.5 per cent tax rate helped attract global tech and pharmaceutical companies and has led to bumper returns....
...In second place, with five promotions and demotions, is Hikma Pharmaceuticals....
...Pharmaceutical group Pfizer and law firms Morrison Foerster and Perkins Coie opened up applications to their diversity fellowships to students of all races last autumn after lawsuits accused them of racial...
...Buyout groups saw that a chain of vets has far greater bargaining power when it comes to negotiating prices with pharmaceutical companies than an independent clinic, said RBC Capital analyst Charles Weston...
...Novartis recently said it would spin off its generic drugmaking business Sandoz....
...Last week, I tweeted the following: “What do Boeing, the collapsed bridge in Baltimore, shortages of critical pharmaceuticals, Donald Trump’s ridiculous new Spac, and an unprecedented amount of speculation...
...That compares with a 13 per cent gain for the NYSE Arca Pharmaceutical Index over the same period. Eli Lilly commands the higher premium....
...But it’s one of the most important companies in the global biotechnology and pharmaceutical industries, relied upon as a manufacturer of novel and often lucrative drugs....
...“American corporations that want to operate in Europe are going to have to abide by regulations around disclosure and reporting that they have been fiercely lobbying against in the US,” said Mark Campanale...
International Edition